Evidence map›Paper›PMID 29958564›Full record

ReviewSeminars in hematology2018

Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.

Gregory M T Guilcher, Tony H Truong, Santosh L Saraf, Jacinth J Joseph, Damiano Rondelli, Matthew M Hsieh

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Review
  4. Review
  5. Optimizing the right time to start sickle cell therapies.Hematology. American Society of Hematology. Education Program · 2025
    Review
  6. Review
  7. Utilization of Stem Cells in Medicine: A Narrative Review.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Gregory M T GuilcherDepartments of Paediatrics and Oncology, University of Calgary, Calgary, Alberta, Canada.
Tony H TruongDepartments of Paediatrics and Oncology, University of Calgary, Calgary, Alberta, Canada.
Santosh L SarafDepartment of Medicine, Section of Hematology-Oncology, University of Illinois, Chicago, IL.
Jacinth J JosephDepartment of Hematology, Washington Hospital Center/Georgetown University, Washington, DC; Sickle Cell Branch, NHLBI, NIH, Bethesda, MD.
Damiano RondelliDepartment of Medicine, Section of Hematology-Oncology, University of Illinois, Chicago, IL.
Matthew M HsiehSickle Cell Branch, NHLBI, NIH, Bethesda, MD. Electronic address: matthewhs@mail.nih.gov.
University of Calgary · CAUniversity of Illinois Chicago · USMedStar Washington Hospital Center · USNational Institutes of Health · US

Funding

Genetics and Genomics of Sickle Cell Nephropathy.K23HL125984 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SARAF, SANTOSH · 2015 to 2018
$700k
NHLBI NIH HHS K23 HL125984
6 · The paper itself

Abstract

Sickle cell disease (SCD) chronically damages multiple organs over the lifetime of affected individuals. Allogeneic hematopoietic cell transplantation (allo-HCT) is the most studied curative intervention. Fully matched related marrow, peripheral blood derived, or cord blood HCT have the best transplant outcome for symptomatic patients with SCD. For patients with asymptomatic or milder disease who have this donor option available, risks and benefits of HCT should be discussed among the patient, family, treating hematologist, and transplant physician, and decision to proceed to HCT should be individualized. Myeloablative conditioning with busulfan, cyclophosphamide, and ATG has been a commonly employed regimen for children and young adults. Recently, low intensity conditioning with low dose total body irradiation and alemtuzumab is emerging as an efficacious and safe regimen for adults, young adults, and possibly children. Mixed donor chimerism (minimum ≥20% myeloid cells), from myeloablative or nonmyeloablative conditioning regimen, produces robust normal donor erythropoiesis and is sufficient to provide a clinical cure. The proportion of patients remaining on immunosuppression beyond 2 years post-HCT is likely <10% with either myeloablative or low intensity regimens. Late effects from myeloablative or reduced intensity conditioning, or from several more months of immunosuppression in low intensity conditioning may be less common than those observed in HCT for malignant indications. Nonmyeloablative approaches with low toxicities should be the focus of future research efforts. Prevention of GVHD is a shared goal in all approaches of allo-HCT in SCD.

Indexed as

Anemia, Sickle CellChildFemaleHematopoietic Stem Cell TransplantationHumansMaleTissue DonorsTransplantation ConditioningTransplantation, HomologousMatched related donor transplantationMixed chimerismNon-myeloablative conditioningSickle cell disease

Identifiers

PMID29958564
PMCPMC6130892
OpenAlexW2800767974

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.